The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Endogenous estrogens are important regulators of cardiovascular homeostasis in premenopausal women and interfere with the development of hypertension and coronary artery disease. These hormones act via three different estrogen receptors affecting both gene transcription and rapid signaling pathways in a complex interplay. In addition to the classical estrogen receptors ERα and ERβ, which are known mediators of estrogen-dependent vascular effects, a G protein-coupled estrogen receptor termed GPER that is expressed in the cardiovascular system has recently been identified. Endogenous human 17β-estradiol, selective estrogen receptor modulators (SERMs) including tamoxifen and raloxifene, and selective estrogen receptor downregulators (SERDs) such as ICI 182,780 are all agonists of GPER, which has been implicated in the regulation of vasomotor tone and protection from myocardial ischemia/reperfusion injury. As a result, understanding the individual role of ERα, ERβ, and GPER in cardiovascular function has become increasingly complex. With accumulating evidence that GPER is responsible for a variety of beneficial cardiovascular effects of estrogens, this receptor may represent a novel target to develop effective strategies for the treatment of cardiovascular diseases by tissue-specific, selective activation of estrogen-dependent molecular pathways devoid of side effects seen with conventional hormone therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor β
Kuiper, G. G. J. M., Lemmen, J. G., Carlsson, B., Corton, J. C., Safe, S. H., van der Saag, P. T., van der Burg, B., & Gustafsson, J.-Å. (1998) · Endocrinology · doi:10.1210/endo.139.10.6216 · Cited by 4,203 · cited 1×
“Estrone and other endogenous estrogen-based steroids display a low binding affinity for ERα, ERβ, and GPER at physiological concentrations, and their physiological actions are less clear (Kuiper et al., 1998; Revankar et al., 2005; Thomas et al., 2005).”
BackgroundBurt, V. L., Whelton, P., Roccella, E. J., Brown, C., Cutler, J. A., Higgins, M., Horan, M. J., & Labarthe, D. (1995) · Hypertension · doi:10.1161/01.hyp.25.3.305 · Cited by 2,998 · cited 2×
“Indeed, the first decade after menopause is accompanied by an increase in blood pressure (Burt et al., 1995), pointing to a blood pressure-lowering effect of endogenous estrogens (Barton and Meyer,”
BackgroundA transmembrane intracellular estrogen receptor mediates rapid cell signaling
Revankar, C. M., Cimino, D. F., Sklar, L. A., Arterburn, J. B., & Prossnitz, E. R. (2005) · Science · doi:10.1126/science.1106943 · Cited by 2,302 · cited 8×
“…of SERMs such as tamoxifen and raloxifene and SERDs such as ICI 182,780 as GPER agonists (Abdelhamid et al., 2011; Filardo et al., 2000; Revankar et al., 2005; Thomas et al., 2005) suggests that many previous studies using these compounds as “pure” agonists/antagonists of ERα and ERβ…”
BackgroundMethodInfluentialSelf-citationGuide to receptors and channels (GRAC), 5th edition
Alexander, S., Mathie, A., & Peters, J. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01649_1.x · Cited by 1,947
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
The ubiquitous role of nitric oxide in cardioprotection
Jones, S. P., & Bolli, R. (2006) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2005.09.011 · Cited by 434
Regulatory role of G protein-coupled estrogen receptor for vascular function and obesity
Haas, E., Bhattacharya, I., Brailoiu, E., Damjanović, M., Brailoiu, G. C., Gao, X., Mueller-Guerre, L., Marjon, N. A., Gut, A., Minotti, R., et al. (2009) · Circulation Research · doi:10.1161/circresaha.108.190892 · Cited by 373 · cited 25×
“G-1 also inhibits endothelin(Meyer et al., 2010), angiotensin II- (Lindsey et al., 2009), and serotonin-dependent (Haas et al., 2009) contractions in certain vascular beds.”
BackgroundInfluentialSelf-citationBopassa, J. C., Eghbali, M., Toro, L., & Stefani, E. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00588.2009 · Cited by 197 · cited 6×
“Similarly, the same treatment reduces infarct size and improves functional recovery in male mice by inhibiting the mitochondria permeability transition pore opening (Bopassa et al., 2010).”
BackgroundInfluential
Cited by
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
The sex difference in haemoglobin levels in adults—mechanisms, causes, and consequences
Murphy, W. G. (2014) · Blood Reviews · doi:10.1016/j.blre.2013.12.003 · Cited by 463
“Human females have higher vessel diameters thanmales, a direct oestrogen effect, consistent with these observations: while direct observation of relative vasodilation in vivo in females has been limited to the larger vessels, increased vascular responsiveness of microvascular beds to agonist inducedvasodilation in fem…”
Arnal, J.-F., Lenfant, F., Metivier, R., Flouriot, G., Henrion, D., Adlanmerini, M., Fontaine, C., Gourdy, P., Chambon, P., Katzenellenbogen, B., et al. (2017) · Physiological Reviews · doi:10.1152/physrev.00024.2016 · Cited by 418
Estrogen biology: New insights into GPER function and clinical opportunities
Prossnitz, E. R., & Barton, M. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.02.002 · Cited by 400
Self-citationFilardo, E. J., & Thomas, P. (2012) · Endocrinology · doi:10.1210/en.2012-1061 · Cited by 366
Metadata
- Authors
- Meyer, M. R., Prossnitz, E. R., & Barton, M.
- Venue
- Vascular Pharmacology
- Publisher
- Elsevier BV
- Published
- 2011-07
- Volume
- 55
- Issue
- 1-3
- Pages
- 17-25
- ISSN
- 1537-1891 (ISSN-L)
- OpenAlex
- W2070023795
- Cited by
- 154
- References
- 9
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. https://app.cochat.ai/papers/10.1016/j.vph.2011.06.003
- The paper
- Meyer, M. R., Prossnitz, E. R., & Barton, M. (2011). The G protein-coupled estrogen receptor GPER/GPR30 as a regulator of cardiovascular function. Vascular Pharmacology. https://doi.org/10.1016/j.vph.2011.06.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.